ArticlePharmacoEconomics2019

Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".

R Brett McQueen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.